ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer
- Experienced Chief Medical Officer to advance ISA´s clinical pipeline
ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination
-- AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019 -- Collaboration seeks to further leverage Moditope® platform
Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz
- Ceremony Conventio Medicinae held at University Medical Center
Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC
- First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer
ISA Pharmaceuticals‘ CSO Prof. Cornelis Melief to Present at CRI-CIMT-EATI-AACR Meeting in New York City
- Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines
ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions
- ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer - Optimum immunotherapy window in cancer identified
Scientific Review Endorses ISA Pharmaceuticals’ Strategy to Overcome Immune Evasion in Cancer Immunotherapy
- Targeting and Activating Dendritic Cells is the Key to Success
ISA Pharmaceuticals Appoints Gerben Moolhuizen as Chief Business Development Officer
- Seasoned executive brings over twenty years of commercial biotech and pharma experience
ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab
- Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and…
ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugates
#8722 Leiden University Medical Center to study novel immunotherapeutic in HPV-positive head neck cancer patients